Article

The study was designed as a single-arm clinical trial. OBJECTIVES:
To investigate the therapeutic effects of detrusor botulinum toxin A (BoNT-A)
treatment in patients with different levels of spinal cord injury (SCI) and types
of detrusor sphincter dyssynergia (DSD). SETTING: Patients with chronic
suprasacral SCI and neurogenic detrusor overactivity (NDO) were treated with
200-U BoNT-A detrusor injection in a tertiary university hospital in Taiwan.
METHODS: Outcome assessment of urodynamic parameters and therapeutic satisfaction
were performed at 3 and 6 months among patients with different demographics, SCI
levels and types of DSD. The treatment outcomes were assessed by changes in
Urogenital Distress Inventory 6-item short form (UDI-6), quality of life (QoL)
index and detrusor pressure at maximum flow rate (Pdet.Qmax). RESULTS: A total of
38 patients with a mean age of 40.1+/-12.4 years and median duration of SCI of
10.3 years were enrolled. Satisfactory response was reported in 23 (60%)
patients. Significant improvements in the UDI-6 and QoL were reported and
significant increases of cystometric bladder capacity and post-void residual were
noted in overall patients after treatment. Patients with different clinical
demographics and urodynamic parameters had similar treatment outcomes and UDI-6
scores. In 11 patients receiving repeat injections of 300 U of BoNT-A after
failure of a previous 200 U injection, the treatment outcomes were not
significantly different, except that the PdetQmax at 6 months were higher in the
group that received 200 U of BoNT-A. CONCLUSION: Patients with different SCI
levels or DSD types had similar treatment outcomes after detrusor 200 U BoNT-A
injections for NDO.

Langue : ANGLAIS